Loading institutional data...
Loading institutional data...
Held by 256 of 5,944 reporting institutions (93th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $32.62 today, the market must believe free cash flow compounds -1.7%/yr for a decade (off $126M normalized FCF).
The market's -1.7% is more conservative than its 9-yr track record.
2-stage DCF · 0.05B shares · net debt -$197M
mean 113.9% · volatility σ 271% · implied rate exceeded in 6/9 yrs
Central path = implied -1.7%/yr growth; shaded band = ±1σ (271%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
7/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $78M buybacks = $78M returned on $87M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: 0%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~7.2% on $50M of debt. Interest last disclosed in FY2019 (no longer broken out).
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.18B 100.0% | $1.11B 100.0% | $1.15B 100.0% | $1.30B 100.0% | $1.13B 100.0% | $892.2M 100.0% | $897.0M 100.0% | $787.3M 100.0% | $712.7M 100.0% | $695.9M 100.0% |
| Cost of Revenue | $681.4M 57.5% | $641.2M 57.7% | $650.3M 56.7% | $707.0M 54.6% | $577.4M 51.0% | $478.9M 53.7% | $460.1M 51.3% | $415.0M 52.7% | $394.1M 55.3% | $378.8M 54.4% |
| Cost of Products | — | — | — | — | — | — | — | — | $304.8M 42.8% | $302.4M 43.5% |
| Cost of Services | — | — | — | — | — | — | — | — | $89.2M 12.5% | $76.4M 11.0% |
| Gross Profit | $503.4M 42.5% | $471.0M 42.3% | $496.8M 43.3% | $589.0M 45.4% | $554.7M 49.0% | $413.3M 46.3% | $436.9M 48.7% | $372.3M 47.3% | $318.6M 44.7% | $317.1M 45.6% |
| Research & Development | $88.7M 7.5% | $90.4M 8.1% | $97.1M 8.5% | $105.0M 8.1% | $75.7M 6.7% | $70.2M 7.9% | $68.6M 7.7% | $64.8M 8.2% | $66.0M 9.3% | $57.8M 8.3% |
| Selling, General & Admin | $409.6M 34.6% | $380.3M 34.2% | $434.6M 37.9% | $486.3M 37.5% | $389.4M 34.4% | $307.6M 34.5% | $289.9M 32.3% | $263.1M 33.4% | $241.5M 33.9% | $237.9M 34.2% |
| Total Operating Expenses | $498.3M 42.1% | $470.7M 42.3% | $531.7M 46.4% | $591.3M 45.6% | $465.1M 41.1% | $377.8M 42.3% | $358.6M 40.0% | $327.9M 41.7% | $307.5M 43.1% | $295.7M 42.5% |
| Operating Income | $5.2M 0.4% | $337K 0.0% | -$34.9M -3.0% | -$2.3M -0.2% | $89.5M 7.9% | $35.5M 4.0% | $78.4M 8.7% | $44.4M 5.6% | $11.1M 1.6% | $21.4M 3.1% |
| Interest Expense | — | — | — | — | — | — | $3.6M 0.4% | $7.5M 1.0% | $6.3M 0.9% | $5.3M 0.8% |
| Other Income (Expense), net | $6.2M 0.5% | $25.3M 2.3% | $14.8M 1.3% | -$130K -0.0% | -$23.5M -2.1% | -$6.2M -0.7% | -$4.4M -0.5% | -$8.8M -1.1% | -$6.6M -0.9% | -$8.4M -1.2% |
| Pretax Income | $11.3M 1.0% | $25.6M 2.3% | -$20.1M -1.8% | -$2.5M -0.2% | $66.0M 5.8% | $29.3M 3.3% | $73.9M 8.2% | $35.6M 4.5% | $4.5M 0.6% | $13.0M 1.9% |
| Income Tax Expense | $9.3M 0.8% | $13.1M 1.2% | $263K 0.0% | -$8.1M -0.6% | -$11.8M -1.0% | -$2.8M -0.3% | $12.6M 1.4% | -$2.1M -0.3% | -$26.0M -3.6% | $3.2M 0.5% |
| Net Income | $2.1M 0.2% | $12.5M 1.1% | -$20.4M -1.8% | $5.6M 0.4% | $77.8M 6.9% | $32.2M 3.6% | $61.3M 6.8% | $37.7M 4.8% | $30.5M 4.3% | $9.8M 1.4% |
| Per Share | ||||||||||
| EPS (Basic) | $0.04 | $0.27 | $-0.45 | $0.13 | $1.79 | $0.76 | $1.48 | $0.96 | $0.81 | $0.27 |
| EPS (Diluted) | $0.04 | $0.27 | $-0.45 | $0.12 | $1.62 | $0.74 | $1.43 | $0.93 | $0.79 | $0.26 |
| Weighted Avg Shares (Basic) | 46.0M | 46.0M | 45.2M | 44.4M | 43.5M | 42.6M | 41.5M | 39.2M | 37.5M | 36.2M |
| Weighted Avg Shares (Diluted) | 46.4M | 46.3M | 45.2M | 45.9M | 47.9M | 43.7M | 42.9M | 40.6M | 38.7M | 36.9M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 14-yr range · 26th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 219.2× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 52.7 | 51.3 | 53.7 | 51.0 | 54.6 | 56.7 | 57.7 | 57.5 |
| Gross Profit | 47.3 | 48.7 | 46.3 | 49.0 | 45.4 | 43.3 | 42.3 | 42.5 |
| R&D | 8.2 | 7.7 | 7.9 | 6.7 | 8.1 | 8.5 | 8.1 | 7.5 |
| SG&A | 33.4 | 32.3 | 34.5 | 34.4 | 37.5 | 37.9 | 34.2 | 34.6 |
| Operating Income | 5.6 | 8.7 | 4.0 | 7.9 | -0.2 | -3.0 | 0.0 | 0.4 |
| Income Tax | -0.3 | 1.4 | -0.3 | -1.0 | -0.6 | 0.0 | 1.2 | 0.8 |
| Net Income | 4.8 | 6.8 | 3.6 | 6.9 | 0.4 | -1.8 | 1.1 | 0.2 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on OMCL: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| OMCL | $1.5B | 810.8× | 15.1× | 1.2× | 6.5% | 42.5% | 0.2% | 0.2% | 0.2% | — | 256 |
Peers = companies sharing OMCL's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.